U.S. Appeals Court Decision Bolsters Merck’s Patent Protection on Anesthesia Drug

The U.S. Court of Appeals for the Federal Circuit recently delivered a significant decision in favor of Merck & Co., concerning the status of a reissued patent connected to a popular drug used to counteract anesthesia. The appellate court concluded that the reissued patent cannot be considered as having been “issued” at its original award date. This ruling effectively maintains Merck’s stronghold on its lucrative pharmaceutical product, as it quashes the intentions of generic drug manufacturers seeking to introduce competing versions. Further details on this ruling can be examined in the report from Law360.